2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5878 Modeling myeloid cell-mediated suppression of CAR T cells

Federico Mazzon, MD, Francesca Albano, PhD2, Annamaria Cesarano, MS3, Luke Saville, PhD4, Rachel Jimenez, PhD5, Meghan A. Menges6, Doris K. Hansen, MD7, Frederick L. Locke, MD8, Ly Vu, PhD9, Paulo Rodriguez, PhD10, Fabiana Perna, MD, PhD11
1 Moffitt Cancer Center, Tampa, United States
2 Moffitt Cancer Center, Tampa, United States
3 Moffitt Cancer Center, Tampa, United States
4 British Columbia Cancer Research Institute, Vancouver, British Columbia, Canada
5 Moffitt Cancer Center, Tampa, United States
6 Moffitt Cancer Center, Tampa, United States
7 Moffitt Cancer Center, Tampa, United States
8 Moffitt Cancer Center, Tampa, United States
9 British Columbia Cancer Research Institute, Vancouver, British Columbia, Canada
10 Moffitt Cancer Center, Tampa, United States
11 Moffitt Cancer Center, Tampa, United States

Although chimeric antigen receptor (CAR) T-cell therapies have achieved high remission rates in hematologic malignancies, many patients relapse, underscoring the need to understand and target resistance mechanisms. We demonstrated that an elevated frequency of monocytic myeloid-derived suppressor cells (M-MDSCs) in patient apheresis is a strong predictor of poor response to CAR T-cell therapy.

Here, we model the interaction between M-MDSCs and CAR T-cells.

We isolate healthy donor CD14⁺ mononuclear cells and generate cytokine-induced CD11b⁺CD33⁺CD14⁺CD15⁻HLA-DRlow/− cells that define M-MDSCs. We engineer CAR T-cells from donor-matched CD3+ cells and set up co-cultures at different ratios. At multiple time points, we analyze CAR T-cell proliferation, immunophenotype and cytotoxicity comparing M-MDSC-exposed CAR T-cells with CAR T-cells alone. Experiments are performed in triplicates across three donors.

To further investigate the impact of M-MDSCs on CAR T-cell function, we co-inject cytokine-differentiated CD14+ cells and healthy-donor-matched CAR T-cells into NSG mice upon injection of NALM6 cells. Mice treated with CAR T-cells alone or with undifferentiated CD14⁺ cells serve as controls. Five mice per group and three independent donors are used. We measure tumor burden by bioluminescence imaging (BLI) and CAR T-cell expansion by flow-cytometry weekly. We FACS-sort CAR T-cells from spleens and perform bulk RNAseq.  Oxford Nanopore long-read sequencing is also employed to characterize poly(A) tail lengths, RNA modifications (m6A and m5C) and alternative splicing at the transcript level.

Further, we collect and analyze multiple apheresis products from patients with non-Hodgkin Lymphoma undergoing CAR T therapy and select 6 samples that contain a population of  M-MDSCs either higher than 20% (3 samples) or less than 5% (3 samples) among CD3-CD19- analyzed cells by flow-cytometry. We virally infect the apheresis products to express CARs and inject these cells into NSG tumor-bearing mice.

We show that exposure to M-MDSCs significantly suppresses CAR T cell proliferation in vitro, resulting in a twofold relative reduction. It impairs killing activity against target cancer cells and increases expression levels of TIM-3, PD-1, and TIGIT. Moreover, in CAR T cells conditioned with M-MDSCs, we find increased differentiation states compared to naïve and central memory subsets.

Consistent with the in vitro findings, tumor-bearing mice receiving CAR T cells and donor-matched ex-vivo differentiated M-MDSCs exhibit impaired tumor control and significantly reduced overall survival. We also find decreased CAR T cell numbers in the peripheral blood, spleen, and bone marrow of mice.

At the molecular level, CAR T cells from the mouse spleen at the endpoint show reduced expression of genes related to CAR T cell activation, proliferation and effector functions. Long-read and multi-omic analyses reveal widespread poly(A) tail shortening, altered RNA modifications, isoform usage and disruption of chromatin organization at these immune regulatory sites. Further, we find dysregulation of epigenetic modifiers such as RING1 and EHMT2/G9a, indicating coordinated transcriptional and epigenetic alterations of key regulatory mechanisms in CAR T-cells injected with M-MDSCs.

Finally, CAR T-cells manufactured from patient apheresis with >20% M-MDSCs show diminished expansion in mice compared to CAR T-cells from apheresis with <5% M-MDSCs. Consistently, we observe reduced tumor control and statistically significant inferior mouse survival in the first group. Notably, both groups of mice injected with patient-derived cells exhibit reduced survival compared to mice injected with CAR T-cells engineered from healthy donors.

Our study supports a critical role for M-MDSCs on CAR T cell efficacy. By modeling the interaction between M-MDSCs and CAR T cells, we find that M-MDSCs negatively impact CAR T cell proliferation in vitro and reduce CAR-T cell numbers in the blood, spleen and bone marrow of mice. CAR T-cell killing is dramatically impaired in co-culture, impacting tumor control in vivo over time. The identification of specific molecular mechanisms underpinning impaired functioning of M-MDSC-exposed CAR T-cells suggests a novel strategy to overcome myeloid-mediated suppression and improve current CAR T therapies.

Federico Mazzon, MD: No relevant conflicts of interest to declare.